文献速递神经免疫

继续或停止疾病修饰治疗的多发性硬化患者新疾病活动风险(DISCOMS):一项多中心、随机、单盲、4期、非劣效性试验

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
PubMed 文献 · Lancet Neurol · 2023-01-01

DISCOMS试验在美国19个多发性硬化中心纳入259例55岁及以上、近5年无复发且近3年无新发MRI病灶的持续接受疾病修饰治疗的患者,随机分为继续治疗组(128例)和停止治疗组(131例)。主要终点为2年内出现新疾病事件(复发或新发/扩大的T2脑MRI病灶)的百分比。继续组6例(4.7%),停止组16例(12.2%),事件率差异7.5个百分点(95%CI 0.6-15.0)。无法拒绝原假设,不能得出停止治疗非劣于继续治疗的结论。

要点

  • 在55岁及以上、近5年无复发且近3年无新发MRI病灶的多发性硬化患者中,停止疾病修饰治疗组2年内新疾病事件率为12.2%,继续治疗组为4.7%。
  • 事件率差异为7.5个百分点(95%CI 0.6-15.0),未能拒绝原假设,无法确定停止治疗是否非劣于继续治疗。
  • 作者认为,对于55岁以上病情稳定的多发性硬化患者,停止疾病修饰治疗可能是合理的选择,但可能与新发MRI活动风险轻度增加相关。

核心结论

  • 无法拒绝原假设,不能得出在55岁以上、近期无复发或新发MRI活动的多发性硬化患者中停止疾病修饰治疗非劣于继续治疗的结论。
  • 对于55岁以上病情稳定的多发性硬化患者,停止疾病修饰治疗可能是合理的选择,但可能与新发MRI活动风险轻度增加相关。

研究设计与样本

  • DISCOMS为多中心、随机、对照、评估者盲、4期、非劣效性试验。
  • 纳入标准:任何亚型多发性硬化、年龄55岁及以上、持续服用获批疾病修饰治疗期间近5年无复发且近3年无新发MRI病灶。
  • 2017年5月22日至2020年2月3日在美国19个多发性硬化中心共纳入259例参与者,按1:1随机分为继续治疗组(128例,49%)和停止治疗组(131例,51%)。
  • 主要终点为2年内出现新疾病事件(多发性硬化复发或新发/扩大的T2脑MRI病灶)的参与者百分比,预设非劣效性界值为8%。

主要发现

  • 继续治疗组6例(4.7%)和停止治疗组16例(12.2%)在2年内出现复发或新发/扩大的脑MRI病灶。
  • 事件率差异为7.5个百分点(95%CI 0.6-15.0)。
  • 继续治疗组与停止治疗组发生不良事件的参与者数分别为109例(85%)和104例(79%),发生严重不良事件的参与者数分别为20例(16%)和18例(14%);停止治疗组不良事件总数(422 vs 347)和严重不良事件总数(40 vs 30)更多。
  • 最常见的不良事件为上呼吸道感染,继续治疗组19例(15%)参与者共20次事件,停止治疗组30例(23%)参与者共37次事件。
  • 继续治疗组3例和停止治疗组4例发生治疗相关不良事件,其中每组各1例为严重不良事件(多发性硬化复发需住院);继续治疗组1例和停止治疗组2例死亡,无死亡被认为与治疗相关。

关键数值与推荐

  • 预设非劣效性界值为8%。
  • 主要终点事件率差异为7.5个百分点(95%CI 0.6-15.0),未能拒绝原假设。

临床怎么用

  • 作者认为,对于55岁以上病情稳定的多发性硬化患者,停止疾病修饰治疗可能是合理的选择,但可能与新发MRI活动风险轻度增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple sclerosis typically has onset in young adults and new disease activity diminishes with age. Most clinical trials of disease-modifying therapies for multiple sclerosis have not enrolled individuals older than 55 years. Observational studies suggest that risk of return of disease activity after discontinuation of a disease-modifying therapies is greatest in younger patients with recent relapses or MRI activity. We aimed to determine whether risk of disease recurrence in older patients with no recent disease activity who discontinue disease-modifying therapy is increased compared to those who remain on disease-modifying therapy. METHODS: DISCOMS was a multicentre, randomised, controlled, rater-blinded, phase 4, non-inferiority trial. Individuals with multiple sclerosis of any subtype, 55 years or older, with no relapse within the past 5 years or new MRI lesion in the past 3 years while continuously taking an approved disease-modifying therapy were enrolled at 19 multiple sclerosis centres in the USA. Participants were randomly assigned (1:1 by site) with an interactive response technology system to either continue or discontinue disease-modifying therapy. Relapse assessors and MRI readers were masked to patient assignment; patients and treating investigators were not masked. The primary outcome was percentage of individuals with a new disease event, defined as a multiple sclerosis relapse or a new or expanding T2 brain MRI lesion, over 2 years. We assessed whether discontinuation of disease-modifying therapy was non-inferior to continuation using a non-inferiority, intention-to-treat analysis of all randomly assigned patients, with a predefined non-inferiority margin of 8%. This trial is registered at ClinicalTrials.gov, NCT03073603, and is completed. FINDINGS: 259 participants were enrolled between May 22, 2017, and Feb 3, 2020; 128 (49%) were assigned to the continue group and 131 (51%) to the discontinue group. Five participants were lost to follow-up (continue n=1, discontinue n=4). Six (4·7%) of 128 participants in the continue group and 16 (12·2%) of 131 in the discontinue group had a relapse or a new or expanding brain MRI lesion within 2 years. The difference in event rates was 7·5 percentage points (95% CI 0·6-15·0). Similar numbers of participants had adverse events (109 [85%] of 128 vs 104 [79%] of 131) and serious adverse events (20 [16%] vs 18 [14%]), but more adverse events (422 vs 347) and serious adverse events (40 vs 30) occurred in the discontinue group. The most common adverse events were upper respiratory infections (20 events in 19 [15%] participants in the continue group and 37 events in 30 [23%] participants in the discontinue group). Three participants in the continue group and four in the discontinue group had treatment-related adverse events, of which one in each group was a serious adverse event (multiple sclerosis relapse requiring admission to hospital). One participant in the continue group and two in the discontinue group died; no deaths were deemed to be related to treatment. INTERPRETATION: We were unable to reject the null hypothesis and could not conclude whether disease-modifying therapy discontinuation is non-inferior to continuation in patients older than 55 years with multiple sclerosis and no recent relapse or new MRI activity. Discontinuation of disease-modifying therapy might be a reasonable option in patients older than 55 years who have stable multiple sclerosis, but might be associated with a small increased risk of new MRI activity. FUNDING: Patient-Centered Outcomes Research Institute and the National Multiple Sclerosis Society.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023. PMID: 37353277. doi:10.1016/S1474-4422(23)00154-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。